Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Investors - Company Overview
Arrayit Corporation (ARYC ) is a leading edge developer, manufacturer and marketer of next-generation life science tools and integrated systems for the large-scale analysis of genomic and proteomic variation, biological function, clinical testing and diagnostics. Using Arrayit’s proprietary technologies, the Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping, gene expression and protein analysis markets, and the Company has entered enter the market for clinical testing with its Clinical Laboratory Improvement Amendments (CLIA) laboratory.
Arrayit has earned respect as a leader in the health care and life sciences industries with its proven expertise in three key areas: the development and support of microarray tools and components, custom printing and analysis of microarrays for research, and the identification and development of clinical microarrays and tools for early detection of treatable disease states.
As a result, Arrayit has provided tools and services to thousands of the leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies worldwide.
The Company’s patented tools and trade secrets provide researchers around the world with the performance, throughput, cost effectiveness and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information. The Company believes this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery, drug development and clinical research, allowing diseases to be detected earlier and permitting better choices of drugs for individual patients.
Forward Looking Statements
Some information contained in or incorporated by reference into this website are “forward looking statements” within the meaning of the United States private securities litigation reform act of 1995. All forward-looking statements involve risks and uncertainties. In particular, any statements regarding pro-forma finances, future sales, results of operations, operating efficiencies and product expansion are subject to known and unknown risks, uncertainties and contingencies. Many of these risks, uncertainties and contingencies are beyond the control of the company and may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. Accordingly, you should not place undue reliance on the forward-looking statements contained in this website. These forward-looking statements speak only as of the date on which the statements were made. In evaluating forward-looking statements, you should consider these risks and uncertainties. The company does not assume any obligation to update any such forward-looking statements to reflect events or circumstances after the date of posting of this information.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.